Literature DB >> 2562940

Role of interleukins in induction and regulation of human IgE synthesis.

S Romagnani1, G Del Prete, E Maggi, P Parronchi, A Tiri, D Macchia, M G Giudizi, F Almerigogna, M Ricci.   

Abstract

Studies of human IgE synthesis are summarized and provide further insight into the cellular and molecular mechanisms involved in IgE regulation, as well as in the alterations responsible for IgE disregulation in some pathological conditions. These include the demonstration that IL-4 is the essential factor for the induction of human IgE syntheses. Another T cell-derived lymphokine, IFN-gamma negatively regulated the IgE synthesis induced by IL-4. These two lymphokines can be produced by different T helper cells, as shown in mice, but they can also be the product of the same T cells clones. Additional cellular and/or molecular signals appear to be involved in the IL-4-induced IgE synthesis, but their precise role in this process is undetermined. Finally, alternations of one or more of these regulatory mechanisms can be detected in patients with pathological conditions characterized by hyperproduction of IgE. In particular, the increased prevalence of T cells clones able to produce IL-4 appears to be a distinctive feature of patients with common atopy whereas a reduction in the proportion of IFN-gamma-producing T cells seems to be peculiar of both patients with hyper-IgE syndrome and patients with AIDS.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2562940     DOI: 10.1016/0090-1229(89)90110-4

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  15 in total

Review 1.  T cells in allergic responses to haptens and proteins.

Authors:  M L Kapsenberg; J D Bos; E A Wierenga
Journal:  Springer Semin Immunopathol       Date:  1992

Review 2.  Cell and molecular biology of chemical allergy.

Authors:  I Kimber; R J Dearman
Journal:  Clin Rev Allergy Immunol       Date:  1997       Impact factor: 8.667

3.  Cold urticaria, raised IgE and HIV infection.

Authors:  R C Yu; B Evans; J J Cream
Journal:  J R Soc Med       Date:  1995-05       Impact factor: 5.344

4.  Characterization of grass pollen reactive T-cell lines derived from lesional atopic skin.

Authors:  C Ramb-Lindhauer; A Feldmann; M Rotte; C Neumann
Journal:  Arch Dermatol Res       Date:  1991       Impact factor: 3.017

5.  Recombinant interferon-gamma inhibits the expression of IL-4 receptors on human lymphocytes.

Authors:  K A Byron; G A Varigos; A M Wootton
Journal:  Clin Exp Immunol       Date:  1991-08       Impact factor: 4.330

Review 6.  The changes in the T helper 1 (Th1) and T helper 2 (Th2) cytokine balance during HIV-1 infection are indicative of an allergic response to viral proteins that may be reversed by Th2 cytokine inhibitors and immune response modifiers--a review and hypothesis.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2004-01       Impact factor: 2.332

7.  Fc epsilon receptor II/CD23+ lymphocytes in atopic dermatitis. III. Aberrant control in the in vitro expression of Fc epsilon RII/CD23 on peripheral blood T cells in atopic dermatitis.

Authors:  T Sakamoto; F Nakayama; T Tamamori; M Takigawa
Journal:  Clin Exp Immunol       Date:  1992-01       Impact factor: 4.330

8.  IgE production in atopic patients is not related to IL-4 production.

Authors:  C T van der Pouw Kraan; R C Aalberse; L A Aarden
Journal:  Clin Exp Immunol       Date:  1994-08       Impact factor: 4.330

9.  HLA-D alleles associated with generalized disease, localized disease, and putative immunity in Onchocerca volvulus infection.

Authors:  C G Meyer; M Gallin; K D Erttmann; N Brattig; L Schnittger; A Gelhaus; E Tannich; A B Begovich; H A Erlich; R D Horstmann
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-02       Impact factor: 11.205

10.  Serum IgE levels of tuberculosis patients in a tropical setup with high prevalence of HIV and intestinal parasitoses.

Authors:  A Kassu; A Mohammad; Y Fujimaki; F Moges; D Elias; F Mekonnen; G Mengistu; M Yamato; Y Wondmikun; F Ota
Journal:  Clin Exp Immunol       Date:  2004-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.